{
  "nci60":{
    "displayName":"NCI-60",
    "fullName": "NCI-60",
    "url":"https://discover.nci.nih.gov/cellminer/datasetMetadata.do",
    "packages":{
      "rcellminerData":{
        "MetaData":[
        	{
        		"dataType":"Drug Activity",
        		"platform":"Sulforhodamine assay",
        		"platformInfo":"Negative log10 (GI50) values of assay",
        		"normalizeMethod":"NA"
        	},
        	{
        		"dataType":"Expression (Z-Score)",
        		"platform":"Multiple",
        		"platformInfo":"Probe intensities combined from four platforms: Agilent Human Genome CGH Microarray 44A, Nimblegen HG19 CGH 385K WG Tiling v2.0, Affymetrix GeneChip Human Mapping 500k Array Set and Illumina Human1Mv1_C Beadchip",
        		"normalizeMethod":"--"
        	},
        	{
        		"dataType":"Expression (Avg. log2 Int.)",
        		"platform":"--",
        		"platformInfo":"--",
        		"normalizeMethod":"--"
        	},
        	{
        		"dataType":"Methylation",
        		"platform":"MassARRAY EpiTYPER",
        		"platformInfo":"500+ target regions scanned using EpiTYPER",
        		"normalizeMethod":"Filtering to exclude Primer Dimer formation"
        	},
        	{
        		"dataType":"Mutations",
        		"platform":"ABI 3730 Sequencer",
        		"platformInfo":"Sequencing for NCI-60 for mutations in known human cancer genes",
        		"normalizeMethod":"NA"
        	},
        	{
        		"dataType":"DNA Copy Number",
        		"platform":"Human Genome CGH Microarray 44A and 44B",
        		"platformInfo":"genome wide variation profiling array for coding and non-coding regions",
        		"normalizeMethod":"Agilent Feature Extraction done with software version 8.1 with default settings for CGH arrays"
        	},
        	{
        		"dataType":"Protein Expression (RPPA)",
        		"platform":"Reverse-phase lysate arrays (RPLA)",
        		"platformInfo":"Antibodies described in AbMiner at http://discover.nci.nih.gov/abminer/",
        		"normalizeMethod":"Dose interpolation analysis done using the DI25 algorithm. described previously (Nishizuka et al, PNAS, 2003)"
        	},
        	{
        		"dataType":"Protein Expression (SWATH-MS)",
        		"platform":"--",
        		"platformInfo":"--",
        		"normalizeMethod":"--"
        	}
        ]
      }
    }
  },
  "ccle":{
    "displayName":"CCLE",
    "fullName": "Cancer Cell Line Encyclopedia",
    "url":"https://portals.broadinstitute.org/ccle/about",
    "packages":{
      "ccleData":{
        "MetaData":[
        	{
        		"dataType":"Drug Activity (-log10[IC50M])",
        		"platform":"Pharmacological Profiling",
        		"platformInfo":"8-point dose response curves",
        		"normalizeMethod":"NA"
        	},
        	{
        		"dataType":"Expression (log2)",
        		"platform":"Affymetrix U133+2 arrays",
        		"platformInfo":"--",
        		"normalizeMethod":"--"
        	},
        	{
        		"dataType":"Mutations",
        		"platform":"Oncomap 3.0 core",
        		"platformInfo":"--",
        		"normalizeMethod":"Quantile normalization"
        	},
        		{
        		"dataType":"DNA Copy Number",
        		"platform":"Affymetrix SNP6.0 Arrays",
        		"platformInfo":"Raw Affymetrix CEL files converted to a single value for each probe set representing a SNP allele or a copy number probe",
        		"normalizeMethod":"Inferred based on estimating probe set specific linear combination curves, followed by most similar HapMap normal samples"
        	}
        ]
      }
    }
  },
	"gdscDec15":{
		"displayName":"GDSC",
		"fullName": "Genomics of Drug Sensitivity in Cancer",
		"url" : "http://www.cancerrxgene.org/help",
		"packages":{
	  "gdscDataDec15":{
	    "MetaData":[
	      	{
	        	"dataType":"Drug Activity (-log10[IC50M])",
        		"platform":"Pharmacological Profiling",
        		"platformInfo":"Fluroesence intensity data on cell viability assays. Cell viability was determined using either a DNA dye (Syto60) or metabolic assay (Resazurin or CellTitre-Glo)",
        		"normalizeMethod":"Dose response curve fit using a multi-level fixed effect model"
	      	},
	      	{
	        	"dataType":"Expression (log2)",
        		"platform":"Affymetrix Human Genome U219 Array",
        		"platformInfo":"E-MTAB-3610 Transcriptional Profiling (Array Express)",
        		"normalizeMethod":"Robust Multi-Array Average (RMA) normalised"
	      	}
	  	 ]
	  	}
		}
  },
  "ctrp":{
    "displayName":"CTRP",
    "fullName": "Cancer Therapeutics Response Portal",
    "url":"http://portals.broadinstitute.org/ctrp/",
    "packages":{
      "ctrpData":{
        "MetaData":[
        	{
        		"dataType":"Drug Activity (AUC)",
        		"platform":"CellTiter-Glo with detection on ViewLux Microplate Imager",
        		"platformInfo":"Measures cellular ATP levels to determine cell number and growth ",
        		"normalizeMethod":"Percent viability curves fit with an area-under-concecentration (AUC) response curve"
        	},
        	{
        		"dataType":"Expression (log2)",
        		"platform":"Affymetrix U133+2 arrays",
        		"platformInfo":"--",
        		"normalizeMethod":"NA"
        	},
        	{
        		"dataType":"Mutations",
        		"platform":"Oncomap 3.0 core",
        		"platformInfo":"--",
        		"normalizeMethod":"NA"
        	},
        		{
	        	"dataType":"DNA Copy Number",
        		"platform":"Affymetrix SNP6.0 Arrays",
        		"platformInfo":"Pharmacological Profiling",
        		"normalizeMethod":"NA"
	      	}
        ]
      }
    }
  },
  "nciSclc":{
    "displayName":"NCI/DTP SCLC",
    "fullName": "NCI/DTP Small Cell Lung Cancer Data Set",
    "url": "NA",
    "packages":{
      "nciSclcData":{
        "MetaData":[
        	{
            "dataType":"Expression (log2)",
        		"platform":"TBD",
        		"platformInfo":"TBD",
        		"normalizeMethod":"NA"
          },
          {
            "dataType":"Drug Activity (-log10[IC50M])",
        		"platform":"TBD",
        		"platformInfo":"TBD",
        		"normalizeMethod":"NA"
          }
       	]
      }
    }
  }
}